Knowles Corporation (KN) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. Knowles Corporation is a manufacturer of specialty electronic components serving medtech, defense, and industrial markets. The company recently completed the sale of its Consumer MEMS Microphones (CMM) segment to Syntiant Corp. in December 2024, which is now reported as discontinued operations. The company operates through two primary segments: Precision Devices (PD) and MedTech & Specialty Audio (MSA).
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenues | $145.9 | $135.2 | $278.1 | $268.5 |
| Gross Profit | $60.6 | $57.8 | $113.9 | $111.0 |
| Gross Margin | 41.5% | 42.8% | 41.0% | 41.3% |
| Operating Earnings | $14.7 | $12.7 | $18.7 | $17.7 |
| Net Earnings (Continuing Ops) | $7.8 | $4.8 | $7.4 | $3.8 |
| Diluted EPS (Continuing Ops) | $0.09 | $0.05 | $0.08 | $0.04 |
| Operating Cash Flow (YTD) | $37.7 | $42.2 | - | - |
| Cash & Equivalents | $103.2 | $84.0 | - | - |
| Total Debt | $190.0 | $202.5 | - | - |
Note: Q2 2024 Net Earnings included a $264.1M loss from discontinued operations due to goodwill impairment. Q2 2025 had no discontinued operations activity.
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 revenue increased 7.9% year-over-year, driven by higher volumes in the MSA segment (sales to Syntiant and hearing health markets) and increased demand in PD's electrification and defense markets.
- Profitability: Operating earnings improved by $2.0M in Q2 2025 compared to Q2 2024. However, GAAP gross margin declined slightly due to a $3.6M impairment charge on machinery and equipment, unfavorable product mix, and production inefficiencies in the CD business.
- Interest Expense: Net interest expense decreased significantly to $2.5M in Q2 2025 from $4.6M in Q2 2024, attributed to lower revolving credit facility balances and reduced imputed interest on the Seller Note.
- Discontinued Operations: The prior year period was heavily impacted by a $249.4M goodwill impairment related to the CMM segment. The current period reflects no such charges.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects 2025 capital expenditures to range between 4% and 6% of revenues.
- Share Repurchases: The company repurchased $35.0M of stock YTD 2025. As of June 30, 2025, $159.0M remains available under the repurchase program.
- Tariff Impact: Following the U.S. announcement of a 10% baseline tariff in April 2025, management does not currently anticipate a material impact on operations but is monitoring trade policy closely.
- Accounting Corrections: The company corrected errors related to stock-based compensation and working capital adjustments in the CMM disposal, resulting in a $1.1M decrease to earnings before taxes for the six months ended June 30, 2025.
- Risks: Key risks include global economic instability, supply chain disruptions, intellectual property litigation, and the ability to realize synergies from the CMM divestiture.
Investor Verification Checklist
- Impairment Details: Verify the nature of the $3.6M impairment charge on machinery and equipment and its impact on future capacity.
- Syntiant Relationship: Review the terms of the ongoing supply agreement with Syntiant (metal can sales) and the $77.2M investment in Syntiant preferred stock.
- Debt Covenants: Confirm continued compliance with the Interest Coverage Ratio (3.00:1) and Total Net Leverage Ratio (3.75:1) covenants under the Credit Facility.
- Non-GAAP Reconciliation: Analyze the reconciliation of GAAP to Non-GAAP metrics, specifically the treatment of stock-based compensation and restructuring charges.
- Working Capital: Monitor the $29.3M in payments related to CMM separation costs and supplier obligations impacting operating cash flow.